Polina has created a CRO business model, which today is the only one providing full scale pharmacovigilance services with full CIS country coverage and EU quality. The only company in the Baltic states with eSolutions department, offering full digitalisation of pharmaceutical companies for eCTD, pharmacovigilance various areas, as well as quality departments (GMP).
Sergey Rud is the General Manager of Proxima Research - the company specializing in the field of systematization of information from the pharmaceutical market and provides different services for the pharmaceutical market in Russian Federation, such as databases support, CRM implementation, business intelligent systems, retail audit, physician prescription audit, market research and consulting.
Mr. Rud graduated from Russian Military Medical Academy with a degree in Surgery in the area of Obstetrics & Gynecology.
After a practice in real medicine as a surgeon, in the beginning of 2000 he started a career in pharmaceutical business. Mr. Rud has many-sided experience in Sales & Marketing on the Pharma market. He worked as a Regional Manager and Market Research Manager in Bayer AG and Eli Lilly & Co.
Graduated from the Geography Department of Kazan Federal University. Received an MBA at the Management School of Lancaster University (UK). Has over 20 years of experience in senior managerial positions in the pharmaceutical industry.
In 2011 won the “Manager of the Year” as per Platinum Ounce award, a prominent professional award in the Russian pharmaceutical field. In 2015, became the Head of the Eurasia business unit — encompassing Russia, the CIS states, Georgia and the Ukraine — in a pharmaceutical company Bosnalijek (Bosnia and Herzegovina), one of the largest pharmaceutical manufacturers in the Balkan States and Eastern Europe. Recently, the business unit led by Valentina has increased its influence by entering the markets of Kazakhstan, Belarus and Azerbaijan.
In 2017, Bosnalijek, with its production sites in Sarajevo, became one of the first companies that had its application approved by the Russian Ministry of Industry and Trade and received a GMP certificate. The Russian market is vital to Bosnalijek’s future; it is the second year in a row that Bosnalijek sales continue to grow at a double-digit rate, which is significantly faster than the market. Bosnalijek best sellers are LYSOBACT and ENTEROFURYL, ranking among Top 3 in their categories.